Company profile

Daiichi Sankyo

Diversified pharma

4568 · TSE · Japan

Public Market Listing

4568TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Daiichi Sankyo are available on Yahoo Finance.

External market data link · No third-party exchange redistribution

Assets

(11 total)

11Total Assets

4Approved

3Phase 3 / Filed

4Phase 1–2 / Early

6Diseases

Showing 11 of 11 assets

		Target & Modality
Datopotamab Deruxtecan	Approved	TROP2Antibody–drug conjugate	Non-Small Cell Lung CancerHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer
Esaxerenone(Minnebro)	Approved	Mineralocorticoid receptorSmall molecule	Hypertension
Quizartinib	Approved	FLT3Small molecule	Acute Myeloid Leukemia
Trastuzumab Deruxtecan	Approved	HER2Antibody–drug conjugate	Non-Small Cell Lung CancerHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer
DS-7011a	Phase 3	Toll-like receptor 7 (TLR7) (inhibitor)	Systemic Lupus Erythematosus
Mirogabalin	Phase 3	α2δ-1 subunit of voltage-gated calcium channelsSmall molecule	Diabetic Peripheral Neuropathic Pain
Patritumab Deruxtecan	Phase 3	HER3Antibody–drug conjugate	Non-Small Cell Lung CancerHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer
DS-3939a	Phase 2	TA-MUC1 (tumor-associated MUC1 glycoform)	Non-Small Cell Lung Cancer
Ifinatamab Deruxtecan	Phase 2	B7-H3Biologic — subtype unspecified	Non-Small Cell Lung Cancer
DS-1103a	Phase 1/2	SIRPα (Signal regulatory protein alpha)	Non-Small Cell Lung Cancer
DS-2243a	Phase 1	HLA-A*02/NY-ESO-1 peptide-MHC complex (tumor) x CD3 (T cells)Small molecule	Non-Small Cell Lung Cancer

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.